Sitagliptin (Januvia) is a DPP-4 inhibitor used along with diet and exercise to improve blood sugar control in type 2 diabetes.
Reviewed by:
Dr. Steve Malen, PharmD
Dr. Steven Blikstein, PharmD
Strength
How would you like to get this medication?
Choose a strength and quantity to continue.
Sitagliptin (Januvia) is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones, which stimulate insulin release and reduce glucagon secretion in a glucose-dependent manner. It is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents such as metformin. Sitagliptin is generally well tolerated with a low risk of hypoglycemia when used alone, though rare cases of acute pancreatitis and severe joint pain have been reported, and dose adjustment is needed in renal impairment.
Complete a health screening
A short questionnaire about your health history and current symptoms — takes about 2 minutes.
Provider reviews your answers
Provider review within 24 hours.
Prescription fulfilled
If approved, your Rx is sent to Invictus Pharmacy and you're notified by text or email. Free nationwide shipping.
Important safety information
Identifying contraindications is vital to prevent adverse outcomes when using Januvia. Absolute contraindications must be strictly adhered to, while cautions guide appropriate use in nuanced clinical contexts.
By understanding and adhering to these contraindications and precautions, both patients and healthcare providers can help ensure Januvia is used safely and effectively.
Brenzavvy (bexagliflozin) is a prescription medication in the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It works by reducing glucose reabsorption in the kidney, thereby increasing urinary glucose excretion and lowering blood sugar. Brenzavvy requires a prescription and should only be taken under the supervision of a healthcare provider. It is not recommended for patients with type 1 diabetes.
Wearable sensor that continuously tracks glucose levels in real time, without fingerstick calibration, for people with diabetes.
Glimepiride is a prescription sulfonylurea used to help control blood sugar levels in adults with type 2 diabetes. It works by stimulating the pancreas to release more insulin, thereby improving glucose utilization and reducing blood glucose levels when combined with diet and exercise. Glimepiride should be taken exactly as prescribed, usually once daily with breakfast or the first main meal. Blood sugar should be monitored regularly, and meals should not be skipped to avoid hypoglycemia.
Glipizide is an oral sulfonylurea medication used to manage type 2 diabetes mellitus. It works by stimulating pancreatic beta cells to release insulin, helping lower blood glucose levels, particularly after meals. Glipizide is typically used alongside dietary modifications and exercise and may be combined with other antidiabetic agents when additional glycemic control is needed. It should be taken 30 minutes before meals, as taking it with food can delay absorption and increase the risk of delayed hypoglycemia. Patients with G6PD deficiency are at increased risk of hemolytic anemia and should be evaluated before starting therapy.
Metformin ER (Glucophage XR) is a prescription medication used to manage type 2 diabetes. It works by reducing glucose production in the liver, enhancing insulin sensitivity, and facilitating the bodys more effective use of glucose. Metformin ER (Generic Glucophage XR) helps reduce blood sugar levels and may also support modest weight loss in some patients. It is usually taken with meals and is available in immediate-release and extended-release forms. Metformin ER is available by prescription only and should be used under a healthcare providers guidance.
Video visitVideo visit required
Januvia, known generically as sitagliptin, is a popular oral medication prescribed to aid in glycemic control in adults with type 2 diabetes. By blocking the dipeptidyl peptidase-4 (DPP-4) enzyme, it facilitates increased insulin secretion and reduced glucose production, helping maintain blood sugar levels after meals.
Developed to work in tandem with lifestyle modifications such as diet and exercise, Januvia is intended for individuals requiring additional glycemic management beyond what lifestyle changes alone can achieve.
Sitagliptin, the active ingredient in Januvia, is a member of the DPP-4 inhibitor class of antidiabetic drugs. Sitagliptin’s targeted action helps stabilize postprandial blood glucose levels, an essential component of comprehensive diabetes management.
Its mechanism inhibits the DPP-4 enzyme, which degrades incretin hormones.
These hormones enhance insulin secretion from pancreatic beta cells in a glucose-dependent manner while reducing glucagon secretion from alpha cells, thereby lowering hepatic glucose production.
The pharmacological profile of sitagliptin includes high bioavailability and a prolonged half-life of once-daily dosing. It is primarily excreted via the urinary system, with minimal metabolism.
Januvia is well-suited to consistent glycemic control, providing patients with a reliable option for managing type 2 diabetes and is often integrated into broader treatment plans alongside other antidiabetic agents.
Januvia’s primary role is to aid in the management of type 2 diabetes by optimizing glycemic control while minimizing postprandial glucose peaks. It is prescribed as part of a comprehensive diabetes management plan to complement dietary and lifestyle changes.
This medication is typically used when diet and exercise alone are insufficient to maintain desired glycemic targets. Doctors frequently prescribe Januvia to accompany other diabetes medications, such as metformin, to bolster glucose control without necessitating daily injections or the intensive management of therapy like insulin.
Currently, there are no significant off-label uses for Januvia. Its application remains primarily focused on its approved indication for the management of type 2 diabetes. Unlike some medications with multiple indications, Januvia’s targeted action is specifically designed to improve glycemic control in diabetes.
Januvia’s mechanism of action and pharmacokinetic profile underline its effectiveness in managing type 2 diabetes. By targeting incretin hormones, both metabolically and pharmacologically, Januvia enhances the body’s physiological responses to glucose.
The therapeutic impact of Januvia stems from its inhibition of the DPP-4 enzyme, which normally degrades incretin hormones. Incretins, such as GLP-1 and GIP, are vital to glucose metabolism, as they stimulate pancreatic β-cell secretion in response to meals.
By preventing their degradation, Januvia prolongs incretin activity, elevating insulin levels during hyperglycemic episodes and reducing glucagon secretion, lowering hepatic glucose output.
This allows glucose-dependent enhancement of insulin release, meaning that insulin production is stimulated more robustly in hyperglycemia, whereas in hypoglycemia, secretion remains largely unaffected, reducing the risk of hypoglycemia compared with other antidiabetic agents.
Januvia’s pharmacokinetic properties support once-daily administration. It has high oral bioavailability (around 87%), making it efficiently absorbed from the gastrointestinal tract. Once ingested, it reaches peak plasma concentrations in about 1–4 hours post-dose.
With a half-life of approximately 12.4 hours, Januvia supports once-daily dosing, leading to stable therapeutic plasma concentrations with minimal variability. Unlike some medications that undergo extensive metabolism, it is primarily excreted unchanged by the kidneys, making it suitable for individuals with specific metabolic considerations.
Appropriate dosing and administration of Januvia are crucial for ensuring optimal glycemic control in individuals with type 2 diabetes.
For patients with moderate to severe renal impairment, doses may be reduced to levels appropriate for their renal function. These adjustments ensure patients receive the therapeutic benefits of Januvia without the risk of excessive drug accumulation.
It is essential for patients to adhere to their prescribed dosing regimen to achieve optimal blood glucose control. Regular monitoring of blood glucose levels and consultation with healthcare providers can improve patient outcomes.
Although Januvia (sitagliptin) is generally well tolerated, some patients may experience side effects ranging from mild to serious. Side effects may be more noticeable during the early stages of treatment, but often improve with continued use.
Patients are encouraged to report any new, unusual, or worsening symptoms to their healthcare provider. With informed awareness and ongoing patient–provider communication, Januvia can be used effectively while minimizing the risk of adverse effects.
Understanding potential drug interactions with Januvia is essential for optimizing therapeutic outcomes and minimizing risks.
Adjusting treatment plans as needed and conducting comprehensive medication reviews help ensure safe concurrent use of Januvia with other therapies, thereby optimizing diabetes management.
Administration & Dosage
Januvia is typically administered as an oral tablet once daily. It may be taken with or without food, according to personal preference or medical advice. Adhering to the healthcare provider's dosage instructions is essential for effective glycemic control.
Januvia should be taken once daily at the same time each day to maintain consistent blood glucose control. Synchronizing the dose with your routine helps ensure you do not miss any doses and allows the medication to achieve maximum efficacy.
Januvia tablets should not be split, crushed, or chewed. They are designed to be swallowed whole to ensure proper release and absorption of sitagliptin. Altering the tablet's form may affect the medication’s effectiveness.
The cost of Januvia varies with factors such as insurance coverage, pharmacy pricing, and geographic location. Contact your insurance provider or local pharmacies to obtain specific pricing and potentially explore affordability options or alternatives.
Metformin and Januvia are often prescribed together for patients with type 2 diabetes who require additional blood sugar control. The combination enhances glucose regulation through complementary mechanisms, though a healthcare provider's guidance is crucial for safe co-administration.
Uses & Mechanism of Action
Januvia is used to improve glycemic control in adults with type 2 diabetes. It is most effective when combined with an appropriate diet and exercise regimen. It is typically prescribed when other treatments do not provide adequate glucose control.
Sitagliptin, the active component of Januvia, inhibits the enzyme DPP-4. This increases levels of incretin hormones, which enhance insulin secretion and reduce glucagon secretion in response to meals, thereby supporting optimal blood glucose regulation.
Sitagliptin is specifically designed to manage blood glucose levels in individuals with type 2 diabetes. It is not intended for type 1 diabetes or diabetic ketoacidosis. Consult your healthcare provider to understand its appropriateness for your condition.
Januvia is not insulin. It is an oral antidiabetic medication that increases pancreatic insulin secretion and reduces glucagon levels. This differs from insulin therapy, which supplements insulin directly into the body through injections.
Januvia is prescribed for adults with type 2 diabetes to help lower blood sugar levels. It is part of a comprehensive treatment approach that includes lifestyle modifications such as diet and exercise to improve overall diabetes management.
Side Effects & Safety
Common side effects of Januvia may include upper respiratory infections, headaches, and nasal congestion. It's vital to report any unusual symptoms to your healthcare provider to promptly address possible adverse reactions.
A serious side effect associated with Januvia is pancreatitis. This condition involves inflammation of the pancreas, and symptoms to watch for include severe abdominal pain, nausea, and vomiting. Immediate medical attention is required if these symptoms occur.
Januvia is generally considered to have a neutral effect on weight, meaning it does not typically lead to weight gain or loss. If you experience unexplained weight changes while taking Januvia, consult your healthcare provider for evaluation.
While constipation is not a common side effect of Januvia, it can occur in some individuals. If you experience persistent or bothersome constipation while on this medication, discuss it with your healthcare provider for possible solutions or adjustments.
Januvia is generally considered safe for use when prescribed by a healthcare professional. However, like all medications, it comes with potential risks and side effects. It's important to use it as directed and communicate openly with your healthcare team.
Interactions & Contraindications
Combining Januvia and Jardiance may be feasible, as they act through different mechanisms; however, both medications should be combined only under a healthcare provider's guidance to minimize potential interactions and assess efficacy and safety.
Consult a healthcare provider before considering using Januvia and Mounjaro together. Your provider can provide advice tailored to your individual health needs and potential interactions between these medications to manage your diabetes effectively.
Before combining Januvia with Ozempic, consult your healthcare provider. They can evaluate whether this combination is safe and beneficial for your specific condition, taking into account the distinct mechanisms of action of these diabetes treatments.
Farxiga and Januvia can potentially be taken together for comprehensive management of type 2 diabetes, but only under a healthcare provider's guidance. This combination should be monitored closely to ensure optimal efficacy and minimize side effects.
Januvia and Jardiance are different medications. They belong to distinct classes of diabetes treatments: Januvia is a DPP-4 inhibitor, and Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. They regulate blood glucose through distinct mechanisms.
Generic & Alternatives
Expected Release Date: A generic version of Januvia may become available in the U.S. as early as May 2026, following the expiration of its key patent.
Some alternatives to Januvia may offer more competitive pricing. However, these substitutions should only be made under the supervision and guidance of a healthcare provider, ensuring they align with your treatment goals and medical history.
Januvia differs from metformin in both mechanism of action and clinical use. While metformin primarily reduces hepatic glucose production, Januvia modulates hormone levels to regulate blood glucose. Both medications can be part of a comprehensive diabetes treatment plan.
Safety between Januvia and Jardiance can vary based on individual health factors and conditions. Consulting a healthcare provider is crucial for determining which medication provides the most appropriate balance of benefits and risks for managing diabetes.
Januvia and metformin are not directly comparable because they serve different roles and have different mechanisms of action in the management of type 2 diabetes. A healthcare provider will consider your specific health needs, history, and responses to find the best treatment regimen for you.